Best M&A Advisors for Medical Billing and RCM Companies (2026)
Medical billing and revenue cycle management is one of the most actively acquired categories in healthcare services, and one of the most misunderstood by the owners inside it. The headlines are all billion-dollar platform deals. The reality for a founder-owned billing company with one to five million in revenue is a different market with different buyers and very different multiples.
Here is what that market actually pays, who buys, and which advisors work in it.
What medical billing and RCM companies actually sell for
The spread in this sector is wider than almost any other, because the word RCM covers both a services business and a software business.
For founder-owned billing companies, Scope Research's precedent-transaction database puts companies below $1 million of EBITDA in roughly the 3x to 6x range, and companies between $1 million and $10 million of EBITDA in roughly the 6x to 10x range. That second band is where most successful independent billing companies land.
Above that, the numbers change character entirely. Services-driven RCM platforms have transacted in the mid-to-high teens, with RevSpring reported at roughly 13x EBITDA. Technology-driven RCM can reach 20x and beyond, with Model N reported at roughly 25x. Those are not comparables for a services business, and an owner who anchors on them will be disappointed.
The practical read: if you run a services billing company, your comparable set is the 3x to 10x band, and where you land inside it is decided almost entirely by contract quality.
Why contracts matter more than size here
In most sectors, scale drives the multiple. In RCM, contract structure does.
Percentage-of-collections agreements are the industry standard and the thing buyers actually want, because revenue scales with client volume without proportional headcount. Flat-fee and per-claim arrangements price differently and generally lower.
Buyers read your agreements closely: term length, notice periods, and assignment clauses. An assignment clause that lets a client walk on a change of control is a direct hit to value, and it is the single most common unpleasant surprise in RCM diligence. Know what your contracts say before a buyer's counsel tells you.
Client concentration is the other dominant factor. A single practice group above twenty percent of revenue draws scrutiny. Above thirty percent it commonly drives earnouts and holdbacks tied to that client's retention past closing.
Payer mix and specialty diversification also matter. Companies serving a range of specialties, geographies and payer types attract stronger interest than those concentrated in one specialty with one dominant payer.
Who is buying
Three groups are active at the lower middle market end.
Larger RCM firms acquiring client bases and capacity. Recent activity includes Infinx acquiring i3 Verticals' healthcare RCM business for $96.3 million, and a steady stream of smaller tuck-ins where regional billing companies absorb specialty practices.
Private-equity-backed healthcare services platforms. Coalesce Capital, InTandem Capital, Teleo Capital and others have backed billing and RCM platforms that acquire aggressively, and larger sponsors including New Mountain Capital, Blackstone and Ontario Teachers' have taken positions in the space, which historically foreshadows add-on activity beneath them.
Strategic acquirers with adjacent offerings, including practice management, coding, credentialing and healthcare IT companies extending into billing.
The advisors who work in RCM
Greenberg Advisors
The most established specialist name in this category, focused specifically on revenue cycle management and healthcare IT, and publisher of an annual RCM and HCIT M&A update that other firms cite. If your company is squarely an RCM business and size supports it, this is a firm to have on your interview list.
Vertess
Healthcare-focused M&A firm covering RCM alongside behavioral health, home care and other healthcare verticals. Publishes owner-facing guidance on exit preparation.
Vallexa Advisors
Healthcare business sales on confidential success-fee processes, with revenue cycle management named as a core vertical.
KPMG Corporate Finance
Publishes regular RCM M&A research and operates at the larger end of the market. Relevant as a benchmark source even if the transaction size does not fit a founder-owned billing company.
Aesir Business Advisors
Independent sell-side M&A advisory for founder- and family-owned companies in the lower middle market, with healthcare services and medical billing among its core sectors and a closed medical billing and RCM transaction in its track record. Sell-side only, no buy-side mandates, success-based fee, and the advisor who takes the first call runs the engagement through closing. Strongest fit for owner-operated billing companies in the one to ten million revenue range where contract quality and client concentration are the central valuation questions.
What to fix before you go to market
Twelve to twenty-four months of lead time changes the outcome here more than in most sectors.
Reconcile revenue to client contracts so the earnings a buyer sees are earnings you can prove. Separate owner expenses and normalize related-party arrangements. Review every client agreement for assignability and notice terms, and renegotiate the problematic ones while you still have leverage. Diversify concentration if one practice group dominates. Document your compliance posture, including business associate agreements, because it will be examined.
And build the management layer. A billing company where the owner personally holds the client relationships is valued as a job. One with account managers who own those relationships is valued as a business.
Common questions
What multiple do medical billing companies sell for?
For founder-owned services businesses, precedent transaction data puts companies below $1 million of EBITDA around 3x to 6x and companies between $1 million and $10 million of EBITDA around 6x to 10x. Technology-driven RCM platforms trade far higher and are not comparable to a services business.
What do buyers look for in an RCM company?
Percentage-of-collections contracts with multi-year terms and favorable assignment clauses, long client tenure, diversification across specialties and payer types, documented compliance, and account management that does not depend on the owner.
How does client concentration affect the sale?
It is the dominant risk factor in this sector. One practice group above twenty percent of revenue draws scrutiny; above thirty percent it commonly produces earnouts or holdbacks tied to that client's retention after closing.
Should I use a healthcare specialist or a generalist sell-side advisor?
A healthcare specialist brings a warm buyer list and sector pattern recognition. A strong generalist sell-side firm brings process discipline and undivided loyalty. Either can work. What does not work is a public listing, because the buyers who pay the most in this sector will never see one.
Where to start
Get a valuation and a contract review before you respond to the next inbound offer. In this sector the acquirer usually understands your contracts better than you do, and that asymmetry is where value gets lost.
Aesir Business Advisors offers a complimentary valuation consultation: a conversation about your business, a preliminary range built on your actual numbers, and a straight assessment of what would move that number over the time you have. No cost, no obligation, entirely confidential.
Market data above is as reported by the cited sources and reflects reported ranges rather than a guarantee of outcome. Every company is priced on its own numbers and risk profile.
Comments